 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
dendrimers is anticipated to revolutionise treatments for diseases such as cancer. The realisation that
the nano-scale has certain properties needed to solve important medical challenges and cater to unmet
medical needs is driving nano-medical research. Increasingly, research is focusing on the novel
chemical and physical properties of nano-sized materials to develop new applications that improve
human health.
Frost & Sullivan (http://www.healthcare.frost.com) finds that the Drug Discovery Nanotechnology
Market in Europe earned revenues of US$174.2 million in 2005 and estimates this to reach US$545.4
million in 2012. "Within the realm of drug discovery and development, nanotechnology focuses
mainly on improving diagnostic methods as well as developing superior drug formulations and drug
delivery systems to enhance disease therapy," notes Frost & Sullivan's Drug Discovery Team Leader
Dr. Amarpreet Dhiman. "The small size, surface tailorability, improved solubility and multifunctionality
of nano-particles are opening many new avenues of research for biologists." The novel properties of
nano-materials offer the ability to interact with complex biological functions in novel ways that operate
at the very scale of biomolecules. This rapidly growing field allows cross-disciplinary researchers the
opportunity to design and develop multifunctional nano-particles that can target, diagnose and treat
diseases such as cancer.
While nanotechnology products are undoubtedly promising, one major issue that will have to be
addressed is their long-term stability. In particular, nano-particles and nano-materials used for drug
discovery applications can become a cause for concern if they degrade too rapidly or if they remain in
the body for prolonged periods. The need, therefore, is to ensure that they meet optimum levels of
stability.
| ""Within the realm of drug discovery and development, nanotechnology focuses mainly on improving diagnostic methods as well as developing superior drug formulations and drug delivery systems to enhance disease therapy,". Dr. Amarpreet Dhiman Frost & Sullivan |
be harmful to humans and the environment. Current understanding of the potential toxicity of
nano-particles is limited, but research indicates that some of these products may enter the human body
and become toxic at the cellular level, in various body fluids, tissues and/or organs. "The impact of
nano-particle interactions with the body are dependent on their size, chemical composition, surface
structure, solubility, shape and how the individual nano-particles amass together" explains Dr.
Amarpreet Dhiman. "Nano-particles may modify the way cells behave and the potential routes of
exposure include the gastrointestinal tract, skin and lungs."
Nanotechnology-based solutions in drug discovery are still a long way from realisation. The
challenge will be to ensure optimum safety and limited exposure, where the key elements for toxicity
screening should include the physical and chemical characterisation of nano-materials,
tissue cellular assays and animal studies.
"Nanotechnology has an extremely interdisciplinary character having a broad range of disciplines
and the industry must increase awareness about the technology and its potential to encourage dialogue
between nanotechnology and other communities biologists such as chemistry, genomic
engineering and biotechnology," says Dr. Amarpreet Dhiman. "By collaborating together extensively,
the complexity of combining disciplines in nanotechnology will generate new businesses and help
accelerate critical advances."
The Role of Nanotechnology in European Drug Discovery is part of the Drug Discovery and
Diagnostic Technologies Service, which also includes research in the following markets: Advances in
Laboratory Automation in Europe, Drug Discovery Outsourcing Opportunities in India and China
Regulatory Hurdles in European Drug Discovery. All research included in subscriptions provide
detailed market opportunities and industry trends that have been evaluated following extensive
interviews with market participants. Interviews are available to the press.
If you are interested in a virtual brochure, which provides manufacturers, end users and other
industry participants with an overview of the latest analysis of The Role of Nanotechnology in
European Drug Discovery (B976-55), then send an e-mail to Radhika Menon Theodore, Corporate
Communications, at rmtheodore@frost.com with the following information: your full name, company
name, title, telephone number, e-mail address, city, state, and country. We will send you the
information via email upon receipt of the above information.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the
development of innovative strategies for more than 40 years. The company's industry expertise
integrates growth consulting, growth partnership services, and corporate management training
to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes
Global 1000 companies, emerging companies, and the investment community by providing
comprehensive industry coverage that reflects a unique global perspective and combines ongoing
analysis of markets, technologies, econometrics, and demographics. For more information, click
The Role of Nanotechnology in European Drug Discovery
B976-55
Contact:
Radhika Menon Theodore
Corporate Communications - Europe
P: +91-44-42044541
F: +91-44-24314264
E: rmtheodore@frost.com
Melina Trevino
Corporate Communications - Americas
P: +1-210-247-2440
F: +1-210-348-1003
E: melina.trevino@frost.com
Surbhi Dedhia
Corporate Communications - India
P: +91-22-5001-3431
E: sdedhia@frost.com
Jasminder Kaur
Corporate Communications - Asia Pacific
P: +65-68900937
E: jkaur@frost.com
Sharmin Jassal
Corporate Communications - Australia
P: +612-8247-8900
F: + 612-9252-8066
E: sjassal@frost.com
Keywords in this release: nanotechnology, European drug discovery markets, Europe, drug discovery,
nanotechnology-based products, nano-arrays, dendrimers, nano-medicine, nano-medical research,
nano-scale, cancer, health, nano-sized materials, nano-particles, drug discovery and development,
diagnostic methods, drug formulations, drug delivery systems, disease therapy, biomolecules,
multifunctional nano-particles, nano-materials, drug discovery applications, tissue cellular assays,
genomic engineering, biotechnology
SOURCE Frost & Sullivan
© 2005-2006 NanoPharmaceuticals.org. All rights reserved. No part of this Internet site may be
reproduced without prior written permission of the copyright holder. Terms & Disclaimer
